Study of Tovecimig plus FOLFIRI for second line colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (Tovecimig plus FOLFIRI) for people with metastatic colorectal cancer that has gotten worse after one prior treatment. The goal is to see if the combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colorectal cancer that has spread to other parts of the body.
- You have already had one line of standard therapy for advanced cancer, and it stopped working.
- Your primary tumor has been surgically removed.
- You are at least 18 years old.
- You are in reasonably good health (able to do daily activities) and your blood counts and organ function meet study criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests whether a combination chemotherapy (Folfiri) plus cetuximab works better for people with stage IV colorectal cancer that has specific tumor gene markers and a specific blood-gene type. It may help you shrink tumors or control the cancer if you match the study’s required lab and health criteria.
This trial tests a new drug, ivonescimab, combined with chemotherapy for people whose colorectal cancer has spread to other parts of the body but not to the liver. The goal is to see if this combination works better than current treatments for this specific type of cancer.
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
This trial tests a combination of two drugs, fruquintinib and FOLFIRI chemotherapy, as a second treatment option for people with metastatic colorectal cancer. It is designed for patients who have already received one prior treatment containing oxaliplatin, fluoropyrimidine, and bevacizumab.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.